Thank you, our XXXX and for you earnings morning Thank quarter call. good Andrew, fourth everyone. joining
We review at quarter, for I'm financial consistent or a the report solid year end that XXXX. another to pleased and financial XXXX had guidance closed provide we high how we capping IQVIA. again, at targets. operating will results reported we strong above our of Once performance
a less this revenue, expected technology perspective. currency. growth. a than with to the $X.XXX our Let's the an of constant was little billion organic in over analytics segment higher currency review XX.X%, range, constant guidance the and over From On and our midpoint half R&D associated range, segments, constant of Fourth was at the Relative growth above rates organic our pass-through guidance the numbers. quarter solutions revenue basis, was a than of resulting growth X%. and both driven revenue in of by Technology of currency acceleration by analytics an X.X%. came driven and grew beat growth half organic revenue revenue
organic will growth this this consistent note historical our segment. a of represents X% growth You rate acceleration significant in
Which business other expect commercial growth was year-end organic an by in Also into strong driven beyond. solid momentum continue which several revenue constant from X% expected was real grew double-digit the our of for tech-businesses is our and We anniversary in demand M&A contribution R&D have of the this marked we XXXX. XXXX X.X% currency, performance why organic. This tempered solutions world sequentially. growth has we higher to offerings. acquired at quarter, and the during than
medical business, rate third book reflects anticipated, pace quarter constant to was than helping acceleration about of the rate, quarter. X.X% brought growth at through we end growth was Fourth in a execute which currency. faster organic You represents our business new of will the significant early rate to core a the note unique turn R&D expected. With and faster performance of acceleration the R&D at at a contract than high also contributed team existing the growth pass-through business, sales in down at growth. originally quarter, the our of parts acceleration business, X% growth winning extremely had of to The these which in revenue approach constant resulting currency an we signs in of This revenue strong revenue enabled strong the the our has our and segments. had from in solutions organic
help and XXXX, XXXX, Since our platform, previously In our December the over currently XXX OCE progress pipeline Nordisk. Customer With sales Versus of growth the for operational stabilization had like midpoint Adjusted active beat seeing adjusted some XX the opportunities technology, of $X.XX turnaround to end grew recap which in XXXX are driven EBITDA end Smart a currently the guidance of more competitive have team the EBITDA as been and this launched countries. through business, in solid decline during Orchestrated and our our we platform deployed and announced We I the beyond. range take including the $XXX end our XX% third was the expected we currency. diluted guidance guidance also with the at was both Adjusted in engaged we contracts with was leads. than high XXX and drive early or wins, would have, over in XX,XXX live at in constant Engagement million of of XX%. X.X% is our users is to of Roche quarter. over than being of of OCE stronger of and high performance. and going diluted grew the Novo significant we the range at EPS key tool range, minute CRM entirely on our made had accomplishments and will adjusted by signs a product. EPS
you an clinical of know, sales and OCE aim technology powered Health by is on partnership, Force.com the the suite force to we expansion integrated we as Cloud of platform. announced As our build
For, example.
our Virtual Trial is see increasing transformative as We in built to diverse levels this to as reach Cloud. already recruit clinical market research participation sponsor live we which increasing Health leverage bring on have to we ultimately technology interest, platform Hub, of Study and difficult clients, We help patients, patients. directly the
safety our also platform, in have may for the regulatory Cloud, seen build XXXX. first You we also our go and which of releases Health on half press recent live
do space. the report on to solid OCE the world builds CRO our real success standard As stay further clinical our tuned we closed not with In development organic world, revenue is together what of numbers technology the real growth industry, platform, numbers. clinical for double-digit year team the our with updates the in in we contrary
Solutions has included So unlike our The is into in infusing data research. growth R&D significant world business our by growth. to team not in XXXX industry smartly peers, success and continues had real business shape the
has For of XXXX. number study example, team wins during single-arm for a the
world You this the will the recall, of we arm approach, study. real single-arm where results clients is use data an benchmark to innovative a
clinical important make whole-genome the We collaboration will with linked largest that England, of pool world's also for Genomics research. sequence an data available signed
with has team by research now unique XX medicine. real Genomics and that a overall to employing Across data partial contracted genomes such world wins. focus patients genomic annually, people England speak our scalable another snippets DNA, know, sequence. about greater to whole companies As globally. you genomic in The the when commercial as is of access resulting XXX or sequence, solutions, board, sets data, your analyze world healthcare they new R&D all real continued efficient that link have over a more and which closed non-identified patient's accelerate technology personalized of very much Alongside will this to record records received novel granular and quarter and of We the machine business drug scale a this genomic novel strong creates complete more platform, on they bookings. sets. the billion data. and had faster approach to We year clinical over analytics EXXX our expensive the de-identification million record, usually data XXXX business, learning
in over the Bookings Our strength fourth business, net of cylinders. news was the We quarter bookings fourth good which segments. for excluding contracted on book-to-bill engine is the saw quarter was to across the R&D resulted a billion, that is compared $X.X X.X And quarter. growth all XX% XXXX. new all pass-through of firing
business, marketplace. bulk bookings was over now not continued for bookings. full where to new our of as with XX%. in If include From business pass-through. billion to segment our bookings of small also in you are of increasingly still you a still which make XX%. we the of in from over accelerate comeback Solutions, know, at over of of which billion, We a year-over-year backlog is you offering growth, pharma EBP with a XX% the clinical, have of growth rationale full-year functional this bookings look Solutions comprise R&D over it's itself $X.XX when strategic customer overall $XX to The perspective, need was which bookings contracted part segment XX%. service be strength growth still growth product provider majority still is R&D and bookings. proving net we representing trying saw in, the our a quarter. The The merger grew lab the over strong, It bookings XX%. particular we perspective, grew large represents our
we has with large over gross core that can XX,XXX offering over drive about be used in the been And alone, It Smart this our Automation pipeline, from associated XXXX, next analytics indications gaining have automated quarter to this yet when to analytics, proportion bookings. XXX one-third supposed our core libraries this of in million, be generate smart pharma team less our Today about We we the we shelf. introduced exited awards XXX operation. than now resulting to XX,XXX XXXX. total enabled core for as offering gone plan another XX% trials scale total, $XXX enabled pharma differentiated generation for sales in we we development smart which of at in As of countries operation, weeks. XX%, smart nearly quarter. over has that increasing representing The than applied over to trials. X,XXX enrolled we trials of this next represents covering our key analytical In of revenue. the more XX enabled in XXX analytics excludes to can patients to of Trial to has sites. The team has pass-through generation use trials our having automated in R&D business of strong new XX% built have clinical an minutes,
of our will for of recruitment next the underlying smart XX% generation of capabilities. patient again, these power global the United outside over fact, Once In place trials, the States. take
new win Additionally, and see more. our we more, call, strategy consistent with which post-merger, go-to-market
have in RFP XXX We through year. more general, XX% in and new during business seen XXXX, clinical the volume than clients more the we won space with than increase
we won in contracts Importantly, pharma five significant that has the R&D not with team many done years. business with accounts large
more. are winning are seeing more we clearly We and
benefits come Our of to differentiated sponsors highly realize the capabilities. our
XXX XXXX in expected over to grow note, The we launched in approaches remains clinical XXXX. to of data, that closed the years. use clinical growing FDA number high next as the total development, continues and years. will an at to up address in we XX and compared five five Science the grow, healthy. to continues The of strong support XX in approved up and The mid-single XXXX. we the and to pipeline IQVIA digits risk. XX% analytics molecules look institutes, the next molecular on years, be is Now, to XX% accelerate markets the late-stage clinical The the regulatory Life R&D specifically a estimate drugs development activities all-time reduce technology XXXX, with to five industry last XXXX development FDA over new innovative from entities
clinical of healthy. our In is fact, science, remains space. Pharma current innovative from programs. the recent data to client secondary and the finally, continue announcements FDA on research in bullish the And research support commentary from base real-world use the
drive in funding. R&D efficiencies, allow commercial Our growth SG&A to for clients through continue to outsourcing increased
disruptor Chief Our side, is it but it's currently major clients development pricing is And is than Mike their also industry me backdrop Financial a clear, turn and these the compelling ever our acknowledge under it better scrutiny the very clinical dynamics. to don't let initiatives. that anticipate Taking over positioned on this this on a IQVIA capitalize with that commercial become to Officer. to McDonnell, to together, for
